Active Biotech

Capital Markets Day
24 November 2020

Helén Tuvesson, CEO

Active Biotech

Safe Harbor Statement

- Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements.
- Statements made during the course of this presentation that are forward-looking are based on the company's current beliefs regarding a large number of factors affecting its business. There can be no assurance that (i) the company has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the available information with respect to these factors on which the Company's analysis is based is complete or accurate, (iii) the company's analysis is correct or (iv) the Company's strategy, which is based in part on this analysis, will be successful.
- All forward-looking statements speak only as of the date of this presentation or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by this cautionary statement. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this presentation.

Active Biotech



A new and focused direction for Active Biotech

Detailed analysis has re-directed our efforts

- **Ongoing** projects focus on specialist indications within oncology and inflammation with high commercial value
- **Solid** preclinical data supporting the new programs
- **Opportunity** to leverage prior generated data to accelerate development
- **Clear** plan and direction for the selected projects

Finance

- Rights issue of approx. SEK 75 M to finance activities and plans through 2022
- Listed on Nasdaq Stockholm (ticker: ACTI)
  - Market cap of SEK 217 M (USD 25 M) as of 13 November 2020
  - Cash at hand Q3, SEK 30.9 M
- Strong shareholder base, incl MGA Holding (Mats Arnhög), AP3 and AP4

Experienced leadership & board with extensive topic expertise

- **Focused** project-oriented organization
- **Expanded** board with complementary skills
- **Broad** international network of KOLs and experts

Advancing three projects in high value niche indications



Treatment of hematological malignancy - multiple myeloma

Tasquinimod is developed as a novel product class in multiple myeloma

- Academic partnership with Abramson cancer institute, Philadelphia, US
- Phase 1b/2a study ongoing with results from mono therapy expected in H2 2021



Treatment of inflammatory eye disorders – uveitis

Laquinimod is advanced as a novel product for the treatment of uveitis

- Topical eye formulation developed
- Clinical program to start with oral proof-of-principle study in parallel to safety testing of new formulation
- Academic partnership in negotiation



Treatment of advanced or metastatic solid tumors

In partnership with NeoTX Therapeutics*

- Phase 1b/2 study ongoing with results expected early 2021

* Global licensing agreement with NeoTX Therapeutics Ltd. for development and commercialisation of naptumomab, since October 2016

Our key priorities and plans through 2023

Tasquinimod

- Progress ongoing clinical Phase 1b/2a study in multiple myeloma
- Prepare for next clinical confirmatory trial and commercial partnership

Laquinimod

- Initiate proof-of-principle phase 2 study in uveitis with oral laquinimod
- Finalize documentation of an eye drop formulation of laquinimod and initiate a clinical phase 1 safety study

Naptumomab

- Advance development of naptumomab together with NeoTX
- Expand naptumomab use across solid tumor indications in various combinations with standard oncology treatments

Projected clinical milestones through 2023

		2020	2021 H1	2021 H2	2022 H1	2022 H2	2023
TASQUINIMOD		✓ Ph 1b/2a First patient dosed ✓ Academic partnership with Abramson Cancer Center established		Ph 1b/2a-mono **Readout** safety **Start** MTD expansion Ph1b/2a-combo **Start**	Ph 1b/2a-combo **Readout** safety	Ph1b/2a-mono **Readout** prelim response Ph1b/2a-combo **Start** expansion cohort	Ph 2b-mono: **Start**
LAQUINIMOD			Announcement of academic partnership	Ph2-oral: **Start** Ph1-eye formulation **Start**		Ph1-eye formulation **Readout** safety	Ph2-oral **Readout** proof-of-principle
NAPTUMOMAB			Ph1b **Readout** safety **Start** MTD cohort	Ph2-cold tumors **Start** indication cohorts Ph2-NSCLC **Start**	Ph1b MTD cohort: **Readout** Safety and preliminary activity		Ph2-cold tumors **Readout** efficacy Ph2 –NSCLC Readout efficacy

Ongoing and planned clinical trials may be affected by COVID-19. We will provide updates as needed. Cold tumors – poor response to checkpoint inhibition alone, NSCLC –Non-small cell lung cancer

Rights issue 2020/21

- Rights issue of approx. SEK 75 M
- Provision of financial stability to pursue the planned pre-clinical and clinical research activities for tasquinimod and laquinimod
- Subscription commitments and issue guarantees today, from existing shareholders, free-of-charge, of approx. SEK 38.1 M, or appr. 52,5% of the offer
- Final terms and condition to be presented on 25 November 2020

Preliminary timetable

30 November 2020
Extraordinary general meeting

30 December 2020
Last day for trading in the share including the right to participate in the rights issue

4 January 2021
Record date for the right to participate in the rights issue

7 – 21 January 2021
Subscription period

7 – 19 January 2021
Trading in subscription rights

www.activebiotech.com

Active Biotech